Psagot Investment House Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 129.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,510,695 shares of the company’s stock after acquiring an additional 853,603 shares during the period. Teva Pharmaceutical Industries accounts for about 1.1% of Psagot Investment House Ltd.’s investment portfolio, making the stock its 26th largest holding. Psagot Investment House Ltd. owned about 0.15% of Teva Pharmaceutical Industries worth $26,588,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TEVA. Capital Research Global Investors lifted its position in Teva Pharmaceutical Industries by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Franklin Resources Inc. lifted its position in Teva Pharmaceutical Industries by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares during the period. FMR LLC lifted its position in Teva Pharmaceutical Industries by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares during the period. Macquarie Group Ltd. lifted its position in Teva Pharmaceutical Industries by 350.3% during the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after acquiring an additional 3,429,448 shares during the period. Finally, Capital World Investors raised its holdings in Teva Pharmaceutical Industries by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after buying an additional 3,268,200 shares during the last quarter. 52.05% of the stock is owned by institutional investors.

Several research analysts have issued reports on the stock. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Tuesday. Royal Bank Of Canada set a $11.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a report on Wednesday, November 29th. Mizuho lifted their target price on shares of Teva Pharmaceutical Industries from $12.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, November 29th. BTIG Research set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, Cantor Fitzgerald set a $10.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Monday, November 27th. Seven equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $21.65.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up $0.01 during mid-day trading on Wednesday, hitting $15.06. 10,220,100 shares of the stock were exchanged, compared to its average volume of 15,647,090. Teva Pharmaceutical Industries Limited has a 52-week low of $10.85 and a 52-week high of $38.31. The company has a market capitalization of $15,290.80, a price-to-earnings ratio of 3.48 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.26%. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/06/psagot-investment-house-ltd-acquires-853603-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.